These sales are routine post-earnings liquidity events at a mega-cap pharma. No bearish read-through, the dollar value is negligible relative to market cap and the timing aligns with standard blackout-window openings. Monitor for any unexpected C-suite sales (CEO/CFO) which would carry more signal.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 14 $135.84entry
- T+1 · 3mo ago +0.10%α +0.57% · $135.97
- T+5 · 3mo ago +12.30%α +13.67% · $152.55
- T+20 · 2mo ago +6.63%α +8.62% · $144.85
- T+60 · 8d ago +9.10%α +11.90% · $148.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Merck EVPs sold a combined $2.81M in open-market stock over the past week, following the company's Q2 earnings beat and raised sales guidance. The sales are small relative to Merck's $327.9B market cap (~0.0009%), making them routine portfolio adjustments rather than a bearish signal. The cluster occurs 9 days post-earnings, a common window for planned sales after blackout periods lift.
Key Financial Metrics
Key Facts
- EVP Richard DeLuca sold ~45,320 shares across four transactions totaling ~$5.94M (Aug 10-12).
- EVP Chirfi Guindo sold 10,000 shares for $1.35M on Aug 13.
- Total cluster value of $7.29M represents ~0.002% of Merck's $327.9B market cap.
- Sales occurred 6-9 days after Merck's Q2 earnings beat (Aug 4), a typical post-blackout window.
- Merck raised FY2026 sales guidance to $66.3B-$67.3B but lowered EPS guidance due to acquisition charges.
Financial Impact
Total insider sales of $7.29M are immaterial relative to $327.9B market cap (0.002%).
Risk Factors
- Insider sales at mega-caps are almost always liquidity-driven; no material risk signaled here.
- If additional C-suite sales emerge in the next 30 days, the pattern would warrant closer scrutiny.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MRK-1786654971985 |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $147.76 −0.00% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $147.76 −0.20% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Entry $144.67 Now $147.76 +2.14% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $147.76 −2.14% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $147.76 +2.14% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $147.76 +0.98% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $147.76 +1.71% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $147.76 +0.35% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $147.76 +1.24% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $147.76 +1.24% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers